Motion sickness susceptibility

Autonomic Neuroscience: Basic and Clinical

Volumn 129, Issue 1-2, 2006, Pages 67-76

  Golding, John F ^a  

^a UNIVERSITY OF WESTMINSTER   (United Kingdom)

Author keywords

Evolution; Individual differences; Motion sickness; Perception; Personality; Pharmacology; Vestibular

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; ANTIEMETIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BETAHISTINE; CETIRIZINE; CHLORPHENIRAMINE; CINNARIZINE; CORTICOSTEROID; DEXAMETHASONE; DEXAMPHETAMINE; DIMENHYDRINATE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DROPERIDOL; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; LOPERAMIDE; LORAZEPAM; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROKININ 1 RECEPTOR ANTAGONIST; OPIATE; PHENYTOIN; PROMETHAZINE; RIZATRIPTAN; SCOPOLAMINE; SEROTONIN 3 ANTAGONIST; TAMOXIFEN; UNINDEXED DRUG; ZAMIFENACIN;

ACCELERATION; ARTICLE; BEHAVIOR; CARDIOVASCULAR REFLEX; DIFFERENTIATION; DISEASE PREDISPOSITION; DROWSINESS; FREQUENCY ANALYSIS; HABITUATION; HUMAN; INDIVIDUALITY; MOTION; MOTION SICKNESS; NONHUMAN; PERSONALITY; PREDICTION; PRIORITY JOURNAL; PROVOCATION; SEDATION; SENSITIZATION; SENSORY SYSTEM; SIDE EFFECT; STIMULUS RESPONSE; VESTIBULAR STIMULATION; VESTIBULAR SYSTEM;

ANIMALS; ANTIEMETICS; DISEASE SUSCEPTIBILITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOTION SICKNESS;

EID: 33749120498     PISSN: 15660702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autneu.2006.07.019     Document Type: Article

References (93)

1. Ahmed S., Sileno A.P., deMeireles J.C., Dua R., Pimplaskar H.K., Xia W.J., Marinaro J., Langenback E., Matos F.J., Putcha L., Romeo V.D., and Behl C.R. Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. Pharm. Res. 17 (2000) 947-974
2. Albert E.G. Phenytoin for the prevention of motion sickness. Med. J. Aust. 178 (2003) 535-536
3. Balaban C.D. Vestibular autonomic regulation including motion sickness and the mechanism of vomiting. Curr. Opin. Neurol. 12 (1999) 29-33
4. Baloh R.W. Advances in neuro-otology. Curr. Opin. Neurol. 11 (1998) 1-3
5. Benson A.J. Motion sickness. In: Ernsting J., Nicholson A.N., and Rainford D.S. (Eds). Aviation Medicine (1999), Butterworth Ltd, Oxford, UK
6. Bertalanffy P., Hoerauf K., Fleischhackl R., Strasser H., Wicke F., Greher M., Gustorff B., and Kober A. Korean hand acupressure for motion sickness in prehospital trauma care, a prospective, randomized, double-blinded trial in a geriatric population. Anesth. Analg. 98 (2004) 220-223
7. Bos J.E., and Bles W. Modelling motion sickness and subjective vertical mismatch detailed for vertical motions. Brain Res. Bull. 47 (1998) 537-542
8. Bos J.E., MacKinnon S.N., and Patterson A. Motion sickness symptoms in a ship motion simulator, effects of inside, outside, and no view. Aviat. Space Environ. Med. 76 (2005) 1111-1118
9. Brey R.L. Both migraine and motion sickness may be due to low brain levels of serotonin. Neurology 654 (2005) E9-E10
10. Buckey J.C., Alvarenga D., Cole B., and Rigas J.R. Chlorpheniramine for motion sickness. J. Vestib. Res. 14 (2004) 53-61
11. Cheung B., and Hofer K. Desensitization to strong vestibular stimuli improves tolerance to simulated aircraft motion. Aviat. Space Environ. Med. 76 (2005) 1099-1104
12. Cheung B.S.K., Money K.E., and Jacobs I. Motion sickness susceptibility and aerobic fitness, a longitudinal study. Aviat. Space Environ. Med. 61 (1990) 201-204
13. Cheung B.S., Heskin R., and Hofer K.D. Failure of cetirizine and fexofenadine to prevent motion sickness. Ann. Pharmacother. 37 (2003) 173-177
14. Cowings P.S., and Toscano W.B. Autogenic-feedback training exercise is superior to promethazine for control of motion sickness symptoms. J. Clin. Pharmacol. 40 (2000) 1154-1165
15. Diamond S.G., and Markham C.H. Prediction of space motion sickness susceptibility by disconjugate eye torsion in parabolic flight. Aviat. Space Environ. Med. 62 (1991) 201-205
16. Dobie T., McBride D., Dobie Jr. T., and May J. The effects of age and sex on susceptibility to motion sickness. Aviat. Space Environ. Med. 72 (2001) 13-20
17. Dornhoffer J., Chelonis J.J., and Blake D. Stimulation of the semicircular canals via the rotary chair as a means to test pharmacologic countermeasures for space motion sickness. Otol. Neurotol. 25 (2004) 740-745
18. Draper, M.H., 1998. The adaptive effect of virtual interfaces, vestibulo-ocular reflex and simulator sickness. PhD Thesis, University of Washington.
19. Drummond P.D. Effect of tryptophan depletion on symptoms of motion sickness in migraineurs. Neurology 654 (2005) 620-622
20. Finley Jr. J.C., O'Leary M., Wester D., MacKenzie S., Shepard N., Farrow S., and Lockette W. A genetic polymorphism of the alpha2-adrenergic receptor increases autonomic responses to stress. J. Appl. Physiol. 96 (2004) 2231-2239
21. Flanagan M.B., May J.G., and Dobie T.G. Sex differences in tolerance to visually-induced motion sickness. Aviat. Space Environ. Med. 76 (2005) 642-646
22. Gianni L., Colleoni M., Golding J.F., and Goldhirsch A. Can tamoxifen relieve motion sickness?. Ann. Oncol. 16 (2005) 1713-1714
23. Gil A., Nachum Z., Dachir S., Chapman S., Levy A., Shupak A., Adir Y., and Tal D. Scopolamine patch to prevent seasickness, clinical response vs. plasma concentration in sailors. Aviat. Space Environ. Med. 76 (2005) 766-770
24. Golding J.F. The effect of motion direction on motion sickness induced by low frequency linear oscillation with subjects seated upright. Proceedings of the UK Informal Group meeting on Human Response to Vibration, Army Personnel Research Establishment, Farnborough UK (1993)
25. Golding J.F. Motion sickness susceptibility questionnaire revised and its relationship to other forms of sickness. Brain Res. Bull. 47 (1998) 507-516
26. Golding J.F., and Gresty M.A. Motion sickness. Curr. Opin. Neurol. 18 (2005) 29-34
27. Golding J.F., and Stott J.R.R. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine scopolamine on motion sickness, skin conductance and heart rate. Br. J. Clin. Pharmacol. 43 (1997) 633-6337
28. Golding J.F., Markey H.M., and Stott J.R.R. The effects of motion direction, body axis, and posture, on motion sickness induced by low frequency linear oscillation. Aviat. Space Environ. Med. 66 (1995) 1046-1051
29. Golding J.F., Mueller A.G., and Gresty M.A. A motion sickness maximum around 0.2 Hz frequency range of horizontal translational oscillation. Aviat. Space Environ. Med. 72 (2001) 188-192
30. Golding J.F., Bles W., Bos J.E., Haynes T., and Gresty M.A. Motion sickness and tilts of the inertial force environment, active suspension systems versus active passengers. Aviat. Space Environ. Med. 74 (2003) 220-227
31. Golding J.F., Kadzere P.N., and Gresty M.A. Motion sickness susceptibility fluctuates through the menstrual cycle. Aviat. Space Environ. Med. 76 (2005) 970-973
32. Gordon C.R., Ben-Aryeh H., Spitzer O., Doweck A., Melamed Y., and Shupak A. Seasickness susceptibility, personality factors, and salivation. Aviat. Space Environ. Med 65 (1994) 610-614
33. Gordon C.R., Gonen A., Nachum Z., Doweck I., Spitzer O., and Shupak A. The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance. J. Psychopharmacol. 15 (2001) 167-172
34. Gordon C.R., Doweck I., Nachum Z., Gonen A., Spitzer O., and Shupak A. Evaluation of betahistine for the prevention of seasickness, effect on vestibular function, psychomotor performance and efficacy at sea. J. Vestib. Res. 13 (2003) 103-111
35. Griffin M.J., and Newman M.M. Visual field effects on motion sickness in cars. Aviat. Space Environ. Med. 75 (2004) 739-748
36. Guedry F.E., Rupert A.R., and Reschke M.F. Motion sickness and development of synergy within the spatial orientation system. A hypothetical unifying concept. Brain Res. Bull. 47 (1998) 475-480
37. Hasegawa S., Takeda N., Morita M., Horii A., Koizuka I., Kubo T., and Matsunaga T. Vestibular, central and gastral triggering of emesis, a study on individual susceptibility in rats. Acta Otorhinolaryngol. 112 (1992) 927-931
38. Iasnetsov V.V., Pravdivtsev V.A., Shashkov A.V., Smirnov L.D., Iasnetsov V.V., Kozlov S.B., and Ivanov IuV. Investigation of the anti-motion sickness effect of 3-hydroxypyridine derivatives. Aviakosm Ekol. Med. 39 (2005) 45-50
39. ISO 2631, 1997. International Standard ISO 2631-1, 1997E. Mechanical vibration and shock. Evaluation of human exposure to whole-body vibration: Part 1. General requirements. 2nd ed. Corrected and reprinted. Geneva, International Organisation for Standardization.
40. Javid F.A., and Naylor R.J. Variables of movement amplitude and frequency in the development of motion sickness in Suncus murinus. Pharmacol. Biochem. Behav. 64 (1999) 115-122
41. Javid F.A., and Naylor R.J. Opioid receptor involvement in the adaptation to motion sickness in Suncus murinus. Pharmacol. Biochem. Behav. 68 (2001) 761-767
42. Javid F.A., and Naylor R.J. The effect of serotonin and serotonin receptor antagonists on motion sickness in Suncus murinus. Pharmacol. Biochem. Behav. 73 (2002) 979-989
43. Johnson W.H., Sunahara F.A., and Landolt J.P. Importance of the vestibular system in visually induced nausea and self-vection. J. Vestib. Res. 9 (1999) 83-87
44. Kaufman G.D. Fos expression in the vestibular brainstem, what one marker can tell us about the network. Brain Res. Rev. 50 (2005) 200-211
45. Kennedy R.S., Lanham D.S., Massey C.J., and Drexler J.M. Gender differences in simulator sickness incidence, implications for military virtual reality systems. Safe J. 25 (1995) 69-76
46. Klocker N., Hanschke W., Toussaint S., and Verse T. Scopolamine nasal spray in motion sickness, a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo. Eur. J. Pharm. Sci. 13 (2001) 227-232
47. Klosterhalfen S., Kellermann S., Pan F., Stockhorst U., Hall G., and Enck P. Effects of ethnicity and gender on motion sickness susceptibility. Aviat. Space Environ. Med. 76 (2005) 1051-1057
48. Lawther A., and Griffin M.J. Prediction of the incidence of motion sickness from the magnitude, frequency, and duration of vertical oscillation. J. Acoust. Soc. Am. 82 (1987) 957-966
49. Lawther A., and Griffin M.J. A survey of the occurrence of motion sickness amongst passengers at sea. Aviat. Space Environ. Med. 59 (1988) 399-406
50. Lee Y., Lai H.Y., Lin P.C., Huang S.J., and Lin Y.S. Dexamethasone prevents postoperative nausea and vomiting more effectively in women with motion sickness. Can. J. Anaesth. 50 (2003) 232-237
51. Lentz J.M. Laboratory tests of motion sickness susceptibility. Motion Sickness, Mechanisms, Prediction, Prevention and Treatment. AGARD Conference Proceedings vol. 372 (1984) 29-1-29-9
52. Levine M.E., Chillas J.C., Stern R.M., and Knox G.W. The effects of serotonin 5-HT3 receptor antagonists on gastric tachyarrhythmia and the symptoms of motion sickness. Aviat. Space Environ. Med. 71 (2000) 1111-1114
53. Levine M.E., Muth E.R., Williamson M.J., and Stern R.M. Protein-predominant meals inhibit the development of gastric tachyarrhythmia, nausea and the symptoms of motion sickness. Aliment. Pharmacol. Ther. 19 (2004) 583-590
54. Lien H.C., Sun W.M., Chen Y.H., Kim H., Hasler W., and Owyang C. Effects of ginger on motion sickness and gastric slow-wave dysrhythmias induced by circular vection. Am. J. Physiol.: Gasterointest. Liver Physiol. 284 (2003) G481-G489
55. Lindseth G., and Lindseth P.D. The relationship of diet to airsickness. Aviat. Space Environ. Med. 66 (1995) 537-541
56. Marcus D.A., and Furman J.M. Prevention of motion sickness with rizatriptan, a double-blind, placebo-controlled pilot study. Med. Sci. Monit. 12 (2005) PI1-PI7
57. Miller K.E., and Muth E.R. Efficacy of acupressure and acustimulation bands for the prevention of motion sickness. Aviat. Space Environ. Med. 75 (2004) 227-234
58. Money K.E., and Cheung B.S. Another function of the inner ear, facilitation of the emetic response to poisons. Aviat. Space Environ. Med. 54 (1983) 208-211
59. Morrow G.R. The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy. Cancer 55 (1985) 2766-2770
60. Nachum Z., Shahal B., Shupak A., Spitzer O., Gonen A., Beiran I., Lavon H., Eynan M., Dachir S., and Levy A. Scopolamine bioavailability in combined oral and transdermal delivery. J. Pharmacol. Exp. Ther. 296 (2001) 121-123
61. Nachum Z., Shupak A., Letichevsky V., Ben-David J., Tal D., Tamir A., Talmon Y., Gordon C.R., and Luntz M. Mal de debarquement and posture, reduced reliance on vestibular and visual cues. Laryngoscope 114 (2004) 581-586
62. Nakagawa A., Uno A., Horii A., Kitahara T., Kawamoto M., Uno Y., Fukushima M., Nishiike S., Takeda N., and Kubo T. Fos induction in the amygdala by vestibular information during hypergravity stimulation. Brain Res. 986 (2003) 114-123
63. Nieto J., and Golding J.F. Personality traits and motion sickness susceptibility. Paper Presented at the Annual Psychology Research Forum at the Kings Fund (2006), University of Westminster, London
64. Nunn P.W.G. Seasickness, its causes and treatment. Lancet ii (1881) 1151-1152
65. O'Hanlon J.F., and McCauley M.E. Motion sickness incidence as a function of the frequency and acceleration of vertical sinusoidal motion. Aviat. Space Environ. Med. 45 (1974) 366-369
66. Oman C.M. Motion sickness, a synthesis and evaluation of the sensory conflict theory. Comp. J. Physiol. Pharmacol. 68 (1990) 294-303
67. Otto B., Riepl R.L., Otto C., Klose J., Enck P., and Klosterhalfen S. μ-opiate receptor agonists - a new pharmacological approach to prevent motion sickness?. Br. J. Clin. Pharmacol. 61 (2006) 27-30
68. Pompeiano O., d'Ascanio P., Balaban E., Centini C., and Pompeiano M. Gene expression in autonomic areas of the medulla and the central nucleus of the amygdala in rats during and after space flight. Neuroscience 124 (2004) 53-69
69. Radtke A., Popov K., Bronstein A.M., and Gresty M.A. Vestibular-autonomic control in man, short- and long-latency effects on cardiovascular function. J. Vestib. Res. 13 (2003) 25-37
70. Riccio G.E., and Stoffregen T.A. An ecological theory of motion sickness and postural instability. Ecol. Psychol. 3 (1991) 195-240
71. Reason J.T., and Brand J.J. Motion Sickness (1975), Academic Press, London
72. Reid K., Palmer J.L., Wright R.J., Clemes S.A., Troakes C., Somal H.S., House F., and Stott J.R. Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man. Br. J. Clin. Pharmacol. 50 (2000) 61-64
73. Rolnick A., and Lubow R.E. Why is the driver rarely sick ? The role of controllability in motion sickness. Ergonomics 34 (1991) 867-879
74. Schelgel T.T., Brown T.E., Wood S.J., Benavides E.W., Bondar R.L., Stein F., Moradshahi P., Harm D.L., Fritsch-Yelle J.M., and Low P.A. Orthostatic intolerance and motion sickness after parabolic flight. J. Appl. Physiol. 90 (2001) 67-82
75. Seibel K., Schaffler K., and Reitmeir P. A randomised, placebo-controlled study comparing two formulations of dimenhydrinate with respect to efficacy in motion sickness and sedation. Arzneimittelforschung 52 (2002) 529-536
76. Serrador J.M., Schlegel T.T., Black F.O., and Wood S.J. Cerebral hypoperfusion precedes nausea during centrifugation. Aviat. Space Environ. Med. 76 (2005) 91-96
77. Stewart J.J., Wood M.J., Parish R.C., and Wood C.D. Prokinetic effects of erythromycin after antimotion sickness drugs. J. Clin. Pharmacol. 40 (2000) 347-353
78. Stern R.M., Hu S., LeBlanc R., and Koch K.L. Chinese hyper-susceptibility to vection-induced motion sickness. Aviat. Space Environ. Med. 64 (1993) 827-830
79. Stott J.R.R. Mechanisms and treatment of motion illness. In: Davis C.J., Lake-Bakaar G.V., and Grahame-Smith D.G. (Eds). Nausea and Vomiting, Mechanisms and Treatment (1986), Springer-Verlag, Berlin 110-129
80. Stroud K.J., Harm D.L., and Klaus D.M. Preflight virtual reality training as a countermeasure for space motion sickness and disorientation. Aviat. Space Environ. Med. 76 (2005) 352-356
81. Treisman M. Motion sickness, an evolutionary hypothesis. Science 197 (1977) 493-495
82. Turner M., and Griffin M.J. Motion sickness in public road transport, passenger behaviour and susceptibility. Ergonomics 42 (1999) 444-461
83. van Marion W.F., Bongaerts M.C., Christiaanse J.C., Hofkamp H.G., and van Ouwerkerk W. Influence of transdermal scopolamine on motion sickness during 7 days' exposure to heavy seas. Clin. Pharmacol. Ther. 38 (1985) 301-305
84. Von Gierke H.E., and Parker D.E. Differences in otolith and abdominal viscera graviceptor dynamics, implications for motion sickness and perceived body position. Aviat. Space Environ. Med. 65 (1994) 747-751
85. Weichenthal L., and Soliz T. The incidence and treatment of prehospital motion sickness. Prehosp. Emerg. Care 7 (2003) 474-476
86. Wood C.D., and Graybiel A. Evaluation of 16 antimotion sickness drugs under controlled laboratory conditions. Aerosp. Med. 39 (1969) 1341-1344
87. Wood C.D., Manno J.E., Manno B.R., Odenheimer R.C., and Bairnsfather L.E. The effect of antimotion sickness drugs on habituation to motion. Aviat. Space Environ. Med. 57 (1986) 539-542
88. Yates B.J., Miller A.D., and Lucot J.B. Physiological basis and pharmacology of motion sickness, an update. Brain Res. Bull. 47 (1998) 395-406
89. Yen-Pik-Sang F., Billar J.P., Golding J.F., and Gresty M.A. Behavioral methods of alleviating motion sickness, effectiveness of controlled breathing and music audiotape. J. Travel Med. 10 (2003) 108-112
90. Yen-Pik-Sang F., Golding J.F., and Gresty M.A. Suppression of sickness by controlled breathing during mild nauseogenic motion. Aviat. Space Environ. Med. 74 (2003) 998-1002
91. Yen Pik Sang F., Billar J., Gresty M.A., and Golding J.F. Effect of a novel motion desensitization training regime and controlled breathing on habituation to motion sickness. Percept. Mot. Skills 101 (2005) 244-256
92. Young L.R., Sienko K.H., Lyne L.E., Hecht H., and Natapoff A. Adaptation of the vestibulo-ocular reflex, subjective tilt, and motion sickness to head movements during short-radius centrifugation. J. Vestib. Res. 13 (2003) 65-77
93. Ziavra N.V., Yen Pik Sang F.D., Golding J.F., Bronstein A.M., and Gresty M.A. Effect of breathing supplemental oxygen on motion sickness in healthy adults. Mayo Clin. Proc. 78 (2003) 574-578